Member Highlights - Biweekly newsletter of the International Cytokine & Interferon Society

Member Highlight – ICIS Treasurer Dusan Bogunovic

November 29, 2023

Interview with ICIS Treasurer, Dusan Bogunovic Please tell us your name, degree, where you currently work, positionDusan Bogunovic, PhD, Icahn School of Medicine at Mount Sinai, NY, Professor Where did you do your training?New York University for Ph.D., and Rockefeller for Postdoc Briefly, what is your research about? The Bogunovic [READ MORE]

Member Highlight – ICIS Past-President (2013) Luke O’Neill

November 29, 2023

Luke O’Neill PhD, Trinity College Dublin, Chair of Biochemistry, ICIS Member Highlight [READ MORE]

Member highlight – Rami Bechara

November 12, 2023

Rami Bechara
Pharm.D; Ph.D
Assistant Professor
Université Paris-Saclay, Paris, France [READ MORE]

Member highlight – Curt Horvath

November 8, 2023

Curt M. Horvath, Ph. D. ; Professor in the Department of Molecular Biosciences, Northwestern University, Evanston, Illinois, USA X:@JakStatMan [READ MORE]

Banner Image of ICIS President, Sarah Gaffen

Presidents Message: What the Cytokines Meeting Means to Me

May 5, 2025

If you only attend one conference this year… here’s why it should be Cytokines-2025! Just Right Ever since I attended my first Cytokines conference (Amsterdam, 2000), this meeting has been THE event on my scientific calendar. I admit to being a little biased, but I think Cytokines conferences are perfect [READ MORE]

Person on high peak overlooking the ocean

Member Highlight: Meet Deanna Santer, Ph.D.

May 5, 2025

My lab is passionate about human interferons and especially type III interferons where there is still a lot to learn about! We are interested in how interferons regulate immune responses. However, when I’m not in the lab I like playing sports and hanging out with my family. Scientist should not [READ MORE]

Clinical Trials, contributed by Howard A. Young

Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

May 4, 2025

ClinicalTrials.gov ID NCT05941845 Sponsor Centre Hospitalier Universitaire de Nice Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party) Study Overview – Brief Summary Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 [READ MORE]

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

May 4, 2025

ClinicalTrials.gov ID NCT05870475 Sponsor Institute of Hematology & Blood Diseases Hospital, China Information provided by Institute of Hematology & Blood Diseases Hospital, China (Responsible Party) Study Overview – Brief Summary Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone [READ MORE]

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)

May 4, 2025

ClinicalTrials.gov ID NCT05843786 Sponsor Hospices Civils de Lyon Information provided by Hospices Civils de Lyon (Responsible Party) Study Overview – Brief Summary Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response [READ MORE]

Share this:

Share this:

Share this:

Share this: